Comparing diabetes drugs for heart health in prediabetes
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This trial tests whether certain diabetes medications can help prevent worsening of heart disease in people who have prediabetes (higher than normal blood sugar, but not yet diabetes). It may be a good fit if you have known coronary artery disease and prediabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have coronary artery disease (blockages in heart arteries seen on a CT scan or after a stent procedure)
- You have prediabetes (fasting blood sugar of 100-125 mg/dL or HbA1c 5.7%-6.4%)
- You are not currently taking any diabetes medications other than metformin
- You do not have diabetes, heart failure, severe kidney disease, or a history of pancreatitis
- You are able to safely participate in physical activity
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your genes may change how well a GLP-1–type medicine works to improve prediabetes. It focuses on adults at higher risk of developing diabetes, especially people of Mexican-American background.
This study tests whether a medication can bring blood sugar back to normal in people with heart disease who have prediabetes (higher-than-normal blood sugar). It might help prevent diabetes and improve heart health.
This trial tests if a drug called dapagliflozin (an SGLT2 inhibitor) can help prevent complications in people with prediabetes when added to lifestyle changes. It aims to see if this approach works better than lifestyle changes alone.
This study tests whether a new medication called chiglitazar sodium, combined with a lifestyle program, can help reverse prediabetes (when blood sugar is high but not yet diabetes). It could help you lower your blood sugar and reduce your risk of developing type 2 diabetes.
This trial tests canagliflozin to see if it lowers “vascular inflammation” in people with diabetes and stable coronary artery disease. It may help reduce harmful inflammation signals that can raise future heart risk.
This trial tests if newer diabetes medications can reduce heart risk and help achieve diabetes remission in people newly diagnosed with type 2 diabetes. It may be an option if you have not taken diabetes drugs before or stopped them over three months ago, and your blood sugar and weight are in certain ranges.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.